Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavel Mohr

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 15, 2023
Can antipsychotics prevent transition to psychosis in high-risk population?Pavel Mohr
Neuro Endocrinology Letters|January 31, 2007
Quality of life in the long-term treatment and the role of second-generation antipsychoticsPavel Mohr
Neuro Endocrinology Letters|November 26, 2008
Deep brain stimulation in psychiatryPavel Mohr
The British Journal of Psychiatry : the Journal of Mental Science|November 29, 2002
Ladislav Haskovec and akathisia: 100th anniversaryPavel Mohr, Jan Volavka
The Journal of Clinical Psychiatry|September 13, 2006
Sedative effects of low-dose risperidone in GAD patients and risk of drug interactionsMiloslav Kopecek, Pavel Mohr, Tomas Novak
Casopis Lekaru Ceskych|December 22, 2012
[How to read critically a scientific paper]Pavel Mohr, Cyril Höschl, Jan Volavka
Neuro Endocrinology Letters|February 24, 2005
Ziprasidone-induced galactorrhea: a case reportMiloslav Kopecek, Martin Bares, Pavel Mohr
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|April 26, 2012
Teaching critical appraisal of articles on psychopharmacologyPavel Mohr, Cyril Höschl, Jan Volavka
Psychiatria Danubina|September 28, 2017
A Review of the Epidemiology of Major Depressive Disorder and of its consequences for Society and the individualAnna McKeever, Mark Agius, Pavel Mohr
Frontiers in Psychiatry|February 11, 2022
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?Pavel Mohr, Jirí Masopust, Miloslav Kopeček
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 15, 2023
Can antipsychotics prevent transition to psychosis in high-risk population?Pavel Mohr
Neuro Endocrinology Letters|January 31, 2007
Quality of life in the long-term treatment and the role of second-generation antipsychoticsPavel Mohr
Neuro Endocrinology Letters|November 26, 2008
Deep brain stimulation in psychiatryPavel Mohr
The British Journal of Psychiatry : the Journal of Mental Science|November 29, 2002
Ladislav Haskovec and akathisia: 100th anniversaryPavel Mohr, Jan Volavka
The Journal of Clinical Psychiatry|September 13, 2006
Sedative effects of low-dose risperidone in GAD patients and risk of drug interactionsMiloslav Kopecek, Pavel Mohr, Tomas Novak
Casopis Lekaru Ceskych|December 22, 2012
[How to read critically a scientific paper]Pavel Mohr, Cyril Höschl, Jan Volavka
Neuro Endocrinology Letters|February 24, 2005
Ziprasidone-induced galactorrhea: a case reportMiloslav Kopecek, Martin Bares, Pavel Mohr
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|April 26, 2012
Teaching critical appraisal of articles on psychopharmacologyPavel Mohr, Cyril Höschl, Jan Volavka
Psychiatria Danubina|September 28, 2017
A Review of the Epidemiology of Major Depressive Disorder and of its consequences for Society and the individualAnna McKeever, Mark Agius, Pavel Mohr
Frontiers in Psychiatry|February 11, 2022
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?Pavel Mohr, Jirí Masopust, Miloslav Kopeček
Pageof 7